Ambrx Biopharma Inc. (AMAM) has an overall financial health rating of B- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-03-06.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-03-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-29 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-28 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-02-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
